MAIA Biotechnology announced robust patient enrollment and dosing progress in its pivotal Phase 3 THIO-104 trial, testing ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC). With 29 patients dosed across 34 sites in six countries, the company aims to enroll up to 100 patients by year-end and expects interim survival data in 2027. Ateganosine, a first-in-class telomere-targeting therapy, has shown promising Phase 2 results with median survival of 17.8 months, significantly higher than standard chemotherapy. The therapy has FDA Fast Track designation and targets a large $70 billion global NSCLC market by 2030.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
